Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 88.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 359,580 shares of the biotechnology company’s stock after selling 2,733,012 shares during the period. Assenagon Asset Management S.A. owned 0.17% of BioCryst Pharmaceuticals worth $2,805,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in BCRX. Vanguard Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 6.1% in the third quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock worth $165,393,000 after buying an additional 1,246,633 shares in the last quarter. Deerfield Management Company L.P. grew its position in BioCryst Pharmaceuticals by 159.4% during the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after buying an additional 7,477,000 shares in the last quarter. State Street Corp grew its position in BioCryst Pharmaceuticals by 8.9% during the second quarter. State Street Corp now owns 8,505,392 shares of the biotechnology company’s stock worth $76,208,000 after buying an additional 691,988 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in BioCryst Pharmaceuticals by 22.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 5,225,986 shares of the biotechnology company’s stock worth $39,665,000 after acquiring an additional 947,431 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in BioCryst Pharmaceuticals by 3.1% in the 3rd quarter. Two Sigma Investments LP now owns 4,419,629 shares of the biotechnology company’s stock worth $33,545,000 after acquiring an additional 131,406 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 150,000 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the transaction, the insider directly owned 400,703 shares in the company, valued at $3,666,432.45. This trade represents a 27.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BCRX. Weiss Ratings upgraded BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Wednesday, March 4th. HC Wainwright upped their price objective on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Evercore started coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 target price on the stock. Finally, Royal Bank Of Canada dropped their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Ten analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $19.64.

BioCryst Pharmaceuticals Stock Up 1.3%

NASDAQ BCRX opened at $9.45 on Tuesday. The stock’s 50-day simple moving average is $7.82 and its two-hundred day simple moving average is $7.49. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.31. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of 7.88 and a beta of 0.73.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $1.05. The firm had revenue of $163.28 million during the quarter, compared to analysts’ expectations of $151.32 million. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The company’s revenue for the quarter was up 209.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.13) EPS. On average, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.